Tocilizumab.

Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther (2011) 1.52

Neuroimmune mechanisms of depression. Nat Neurosci (2015) 1.05

Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95

Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress (2016) 0.83

Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol (2014) 0.81

Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations. Int J Gen Med (2015) 0.80

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer (2011) 0.80

Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6. Br J Clin Pharmacol (2015) 0.77

Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep (2014) 0.76

Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmol (2016) 0.76

Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms. Mol Psychiatry (2017) 0.76

Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother (2017) 0.75

Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient. Case Rep Rheumatol (2012) 0.75

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum (2008) 4.96

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis (2010) 3.90

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet (2008) 3.80

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol (2008) 2.42

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31

Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest (2004) 2.16

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis (2008) 2.11

Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov (2007) 1.45

Tocilizumab. Nat Rev Drug Discov (2009) 1.36

JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem (2002) 1.33

Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol (2000) 1.14

Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov (2006) 1.13

Actemra poised to launch IL-6 inhibitors. Nat Biotechnol (2008) 0.96